



# Public Meeting on Independent Third-Party Assessment of IND FDA-Sponsor Communication Practices in PDUFA VI

August 11, 2020

9:30 – 9:35 am	<b>Welcome and Introduction</b>  <b>Emily Ewing</b> , Center for Drug Evaluation and Research, FDA <i>Meeting Facilitator, Program Evaluation and Implementation Staff</i>
9:35 – 10:20 am	<b>Presentation of the Assessment</b>  <b>Valerie Overton</b> , Eastern Research Group <i>Vice President</i>
10:20 – 10:35 am	<b>FDA Perspective</b>  <b>Rachel Kichline</b> , Center for Drug Evaluation and Research, FDA <i>Director, Business Process &amp; Analysis Staff</i>
10:35 – 11:15 am	<b>Industry Perspectives</b>  <b>Eric Larson</b> , AbbVie <i>Senior Manager, Regulatory Affairs (Global Regulatory Strategy, US/Canada)</i>  <b>Todd Paporello</b> , Bayer Pharmaceuticals <i>Vice President and Head of Regulatory Affairs Americas</i>  <b>Cartier Esham</b> , Biotechnology Innovation Organization (BIO) <i>Executive Vice President of Emerging Companies</i>
11:15 – 11:30 am	<b>Break</b>
11:30 – 12:25 pm	<b>Q&amp;A and Open Public Comment</b>
12:25 – 12:30 pm	<b>Closing</b>